|Organic compounds -- part of the class 532-570 series patents - Monitor Patents|
USPTO Class 544 | Browse by Industry: Previous - Next | All
03/2010 | Recent | 15: May | Apr | Mar | Feb | Jan | 14: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Organic compounds -- part of the class 532-570 series March listing by industry category 03/10Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 03/25/2010 > patent applications in patent subcategories. listing by industry category
20100076187 - Fast dissociating dopamine 2 receptor antagonists: The present invention relates to 6-(piperidin-4-ylamino)pyridazin-3-carbonitriles that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent: Philip S. Johnson Johnson & Johnson
20100076188 - Novel carboxylic acid derivatives, their preparation and use: e
20100076189 - Process for the preparation of imatinib and intermediates thereof: It is the object of the present invention a process for the preparation of 4-methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine and analogues thereof, intermediates useful for the synthesis of Imatinib, or 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide.... Agent: Dickstein Shapiro LLP03/18/2010 > patent applications in patent subcategories. listing by industry category
20100069629 - Pyrimidine derivatives as pi3k inhibitor and use thereof: P
20100069630 - Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.... Agent: Lucas & Mercanti, LLP
20100069631 - Integrated process for urea and melamine production: In an integrated process for urea and melamine production, urea is produced in a urea plant (10) comprising a high pressure urea synthesis section (11) from which an aqueous solution comprising urea, ammonium carbamate and ammonia is obtained and a urea recovery section (21) operating at low pressure, and melamine... Agent: Akerman Senterfitt
20100069632 - Salts of pyrrolopyrimidinone derivatives and process for preparing the same: The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric... Agent: Frommer Lawrence & Haug
20100069633 - Paliperidone ketone: e
20100069635 - Rosuvastatin dehydroabietylamine salt: There is provided a compound, which is dehydroabietylamine salt of rosuvastatin. Also provided are processes for making rosuvastatin calcium that include formation of dehydroabietylamine salt of rosuvastatin.... Agent: Dr. Reddy''s Laboratories, Inc.
20100069636 - Quinoxaline derivative, and organic semiconductor device, electric field light emitting device, and electronic device which have the same: A quinoxaline derivative represented by a general formula (1) is provided. In the formula, R1-R12 each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, an acyl group, a nitro group, a cyano group, an amino group, a dialkylamino group, a diarylamino group, a... Agent: Cook Alex Ltd
20100069637 - Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative: This invention provides novel crystalline acid salt forms of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, i.e. sitagliptin, to processes for their preparation and isolation, and to pharmaceutical compositions comprising the same.... Agent: Cohen, Pontani, Lieberman & Pavane LLP
20100069638 - Sulfonamide derivative having pgd2 receptor antagonistic activity: i03/11/2010 > patent applications in patent subcategories. listing by industry category
20100063275 - Process for preparing 6-phenoxypyrimidin-4-ol derivatives in the presence of a quinuclidine or a n-methyl pyrrolidine derivatives: The present invention relates, inter alia, to a process for preparing a compound of formula (I): using a quinuclidine-based catalyst or an optionally 3-substituted N-methyl pryrrolidine-based catalyst.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department
20100063276 - Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2, and m3 receptors: This invention relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine as well as its pharmaceutically acceptable salts for the preparation of a drug having the particularity of treating or preventing urinary incontinence, by local and/or oral route.... Agent: Birch Stewart Kolasch & Birch
20100063277 - Intramolecular c-h amination with sulfonyl azides: Cobalt (II) complexes of porphyrins are effective catalysts for intramolecular nitrene insertion of C—H bonds with arylsulfonyl azides. The cobalt-catalyzed process can proceed efficiently under mild and neutral conditions in low catalyst loading without the need of other reagents or additives, generating nitrogen gas as the only byproduct. Using the... Agent: Bryan Cave LLP
20100063278 - N-formyl hydroxylamines compounds: Novel N-formyl hydroxylamine compounds and their derivatives are discloses. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation... Agent: Mccarter & English, LLP Novartis Institutes For Biomedical Research, Inc.
20100063279 - Method for producing quinolone carboxylic acid derivative: v
20100063280 - Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds: The present invention discloses a novel process to prepare 4-substituted 1-Cyclopropane-sulfonyl-Piperidinyl compounds, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 4-[4-[(R)-[1-[cyclopropylsulfonyl)-4-piperidinyl](3-fluorophenyl)methyl]-3(S)-methyl-1-piperazinyl]-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-methylpiperidine] compounds.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20100063281 - Diphenyl amine derivatives having luminescence property: The present invention relates to diphenyl amine derivatives having luminescent properties, and particularly to diphenyl amines substituted with various electron-donating or electron-withdrawing groups. The compounds of the present invention show blue or blue-green luminescence, and luminescence of the compounds herein can be achieved by UV or visible light, thus being... Agent: Frommer Lawrence & Haug LLP
20100063282 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, R4, R5, R6, X, R7, and R8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20100063283 - Process for stereoselective synthesis of lamivudine: A process for stereoselective synthesis of lamivudine, comprising (a) glycosylation of compounds of formula (I) and cytosine or protected cytosine, separating the resulting products by crystallization to afford intermediates of formula (II); (b) removing the protecting groups of intermediates of formula (II) to obtain lamivudine.... Agent: Dorsey & Whitney LLP Intellectual Property Department
20100063284 - Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1h-benzo[d]imidazol-2-yl)urea: Solid forms of crystalline1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea, compositions containing solid forms of crystalline1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea and methods of using the same are described.... Agent: Vertex Pharmaceuticals Inc.
20100063285 - Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same: The present invention relates to triazole derivaties, a method for the preparation thereof, and a pharmaceutical composition containing the same as an active ingredient. The inventive triazole derivaties have an excellent antifungal activity against various pathogens.... Agent: Sughrue Mion, PLLC
20100063286 - Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same: The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has... Agent: Lowe Hauptman Ham & Berner, LLP03/04/2010 > patent applications in patent subcategories. listing by industry category
20100056779 - Synthesis of methyl nonactate derivatives: Methyl nonactate is converted into a variety of different triazoloamide antibacterial agents by a reaction scheme involving (1) inversion of the secondary alcohol of the methyl nonactate to produce the corresponding azidoester, (2) converting the azido ester to the corresponding azidoamide, and (3) converting the azido group of the azidoamide... Agent: Calfee Halter & Griswold, LLP
20100056781 - Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates: The invention relates to 2,4-dibromoropyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing the intermediate.... Agent: Louis J. Wille Bristol-myers Squibb Company
20100056782 - Hydrogenation processes: Disclosed are heterogeneous processes (i) for the hydrogenation of a compound containing at least one unsaturated carbon-carbon bond, and (ii) for the hydro-dehalogenation of a compound containing at least one C—Cl, C—Br or C—I bond. The processes comprise reacting said compound with a hydrogenating agent and a heterogeneous hydrogenation catalyst... Agent: Hodgson Russ LLP The Guaranty Building
20100056783 - Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof: Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof represented by the general formula-(1) through novel intermediate compounds of general formula-(4).... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20100056784 - Process for the preparation of voriconazole: The present invention relates to an improved process for the preparation of Voriconazole.... Agent: Frommer Lawrence & Haug
20100056785 - Preparation of zopiclone and its enantiomerically enriched isomer: Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine is reacted with 1-chloro-carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates, hydroxides or oxides in a solvent medium to give Zopiclone. It is reacted with optically active acid in a... Agent: Ladas & Parry LLP
20100056786 - Method for producing alkylanilides from halobenzene derivatives: The present invention relates to a novel process for preparing known fungicidally active alkylanilides from 2-alkylhaloaromatics and heterocyclylamides.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.Previous industry: Organic compounds -- part of the class 532-570 series
Next industry: Organic compounds -- part of the class 532-570 series
RSS FEED for 20150611:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Organic compounds -- part of the class 532-570 series patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Organic compounds -- part of the class 532-570 series patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Organic compounds -- part of the class 532-570 series patents we recommend signing up for free keyword monitoring by email.
Advertise on FreshPatents.com - Rates & Info
FreshPatents.com Support - Terms & Conditions
Results in 0.07052 seconds